ClearPoint Neuro, Inc.

NasdaqCM:CLPT Stock Report

Market Cap: US$305.9m

ClearPoint Neuro Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Joe Burnett

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage25.9%
CEO tenure7yrs
CEO ownership0.9%
Management average tenure3.7yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Apr 25
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Joe Burnett's remuneration changed compared to ClearPoint Neuro's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$2mUS$518k

-US$22m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$2mUS$494k

-US$16m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$1mUS$445k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$784kUS$435k

-US$7m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$864kUS$366k

-US$6m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$515kUS$360k

-US$6m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$930kUS$55k

-US$7m

Compensation vs Market: Joe's total compensation ($USD2.00M) is about average for companies of similar size in the US market ($USD2.24M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Burnett (47 yo)

7yrs

Tenure

US$1,995,337

Compensation

Mr. Joseph Michael Burnett, also known as Joe, has been Chief Executive Officer, President and Director of ClearPoint Neuro, Inc. since November 7, 2017. Mr. Burnett has spent his entire career in medical...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Burnett
President7yrsUS$2.00m0.90%
$ 2.8m
Danilo D'Alessandro
Chief Financial Officer3.8yrsUS$930.98k0.18%
$ 548.9k
Jeremy Stigall
Chief Business Officer1.8yrsUS$838.49kno data
Mazin Sabra
Chief Operating Officer2.1yrsno data0.13%
$ 412.4k
Ellisa Cholapranee
General Counsel & Secretary3.6yrsno datano data
Jacqueline Keller
Vice President of Marketing5yrsno datano data

3.7yrs

Average Tenure

41.5yo

Average Age

Experienced Management: CLPT's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Burnett
President7yrsUS$2.00m0.90%
$ 2.8m
R. Fletcher
Independent Chairman of the Board7.5yrsUS$227.62k0.34%
$ 1.0m
B. Johnson
Independent Director5.2yrsUS$189.99k0.14%
$ 417.1k
Lynnette Fallon
Independent Director3.3yrsUS$202.49k0.11%
$ 332.8k
Pascal E. Girin
Independent Director10.2yrsUS$192.65k0.27%
$ 821.6k
Linda Liau
Independent Director3yrsUS$182.49k0.11%
$ 344.9k
Timothy Richards
Independent Director10.7yrsUS$194.75k0.23%
$ 716.7k
Matthew Klein
Director4.6yrsUS$174.99k0.11%
$ 326.3k

6.1yrs

Average Tenure

64yo

Average Age

Experienced Board: CLPT's board of directors are considered experienced (6.1 years average tenure).